Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or Placebo Co-Administered With Varenicline (Champix®) as an Aid in Smoking Cessation

NCT00995033 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.

NCT NCT00995033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00995033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or Placebo Co-Administered With Varenicline (Champix®) as an Aid in Smoking Cessation
Lead sponsor
Maastricht University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
September 30, 2012
Enrollment
558 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

smoking behavior, smoking lapse behavior, smoking relapse behavior